cis-Platinum combination chemotherapy of bladder cancer. An update

S. D. Williams, L. H. Einhorn, J. P. Donohue

Research output: Contribution to journalArticle

18 Scopus citations


The combination of cis-platinum (DDP), adriamycin, and 5-fluorouracil was evaluated in 44 patients with advanced urothelial cancer, 39 of whom were evaluable for response. There were 18 partial remissions (46.2%) and no complete responses. Remissions were clinically meaningful, but of short duration. Four patients had bulky pelvic disease that was made respectable by chemotherapy, but none of these patients remained disease-free. These results are not superior to that expected from DDP as a single agent. In addition, there appears to be little or no survival benefit associated with chemotherapy. DDP represents an advance in the treatment of bladder cancer, but additional active agents and innovative approaches are needed.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalCancer Clinical Trials
Issue number4
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'cis-Platinum combination chemotherapy of bladder cancer. An update'. Together they form a unique fingerprint.

  • Cite this